We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

115 hedge funds and large institutions have $154M invested in Atea Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

8% more funds holding

Funds holding: 106 → 115 (+9)

5.43% more ownership

Funds ownership: 61.57% → 66.99% (+5.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 39

19% less capital invested

Capital invested by funds: $190M → $154M (-$35.5M)

96% less call options, than puts

Call options by funds: $163K | Put options by funds: $3.67M

Holders
115
Holders Change
+9
Holders Change %
+8.49%
% of All Funds
1.51%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
33
Reduced
39
Closed
6
Calls
$163K
Puts
$3.67M
Net Calls
-$3.51M
Net Calls Change
-$3.52M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.07M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$989K
3
Bank of America
Bank of America
North Carolina
+$696K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$577K
5
Group One Trading
Group One Trading
Illinois
+$478K

Top Sellers

Rank Fund Capital Flow
1
AC
Almitas Capital
California
-$1.6M
2
BlackRock
BlackRock
New York
-$715K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$608K
4
BCM
BML Capital Management
Indiana
-$464K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$392K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$24.5M -$715K -209,307 -2%
BCM
2
BML Capital Management
Indiana
$21.7M -$464K -135,849 -2%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$16.9M +$352K +103,015 +2%
TCM
4
Tang Capital Management
California
$14M -$215K -63,000 -1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$13.7M -$608K -177,946 -4%
BCLSI
6
Bain Capital Life Sciences Investors
Massachusetts
$7.21M – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$5.51M -$88.2K -25,836 -1%
State Street
8
State Street
Massachusetts
$5.17M +$25.9K +7,575 +0.4%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$4.47M +$442K +129,453 +9%
Renaissance Technologies
10
Renaissance Technologies
New York
$3.56M -$21.2K -6,200 -0.5%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$2.81M +$177K +51,927 +6%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$2.31M +$325K +95,300 +14%
Northern Trust
13
Northern Trust
Illinois
$1.85M -$127K -37,071 -5%
Charles Schwab
14
Charles Schwab
California
$1.81M -$35.2K -10,298 -2%
JP Morgan Chase
15
JP Morgan Chase
New York
$1.79M -$122K -35,810 -5%
CM
16
CM Management
Florida
$1.45M – – –
NM
17
Newtyn Management
New York
$1.43M -$300K -87,716 -15%
Millennium Management
18
Millennium Management
New York
$1.41M +$1.07M +312,733 +179%
Two Sigma Investments
19
Two Sigma Investments
New York
$1.37M +$357K +104,681 +29%
PLC
20
Peapod Lane Capital
New York
$1.33M +$16.2K +4,748 +1%
Morgan Stanley
21
Morgan Stanley
New York
$1.31M -$320K -93,704 -17%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$1.16M +$369K +107,963 +37%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$1.06M +$577K +168,916 +86%
BPC
24
Banque Pictet & Cie
Switzerland
$1M – – –
Goldman Sachs
25
Goldman Sachs
New York
$986K +$138K +40,483 +14%
1
2 3 4 5

AVIR Hedge Fund Activity: Q3 2025 in Review

115 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2025, worth a combined $154M — down 19% from $190M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AVIR positions and 6 closed out — a net gain of 9 holders — while 33 added to existing stakes and 39 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was Almitas Capital, exiting entirely with an estimated $1.6M sold.

  • 115 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2025, up from 106 in Q2 2025.
  • Funds reported $154M of Atea Pharmaceuticals stock for Q3 2025, down 19% quarter-over-quarter.
  • 15 funds opened new Atea Pharmaceuticals positions in Q3 2025 and 6 closed out, a net change of +9 holders.
  • The largest Atea Pharmaceuticals buyer in Q3 2025 was Millennium Management, an estimated $1.07M added.
  • The largest Atea Pharmaceuticals seller in Q3 2025 was Almitas Capital, an estimated $1.6M sold.

Based on aggregated 13F filings for Q3 2025.